Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexis Baass

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Journal of Clinical Lipidology|April 1, 2023
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemiaMartine Paquette, Sophie Bernard, Bertrand Cariou, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 26, 2021
Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial HypercholesterolemiaMartine Paquette, Sophie Bernard, Bertrand Cariou, et al.
European Journal of Preventive Cardiology|September 1, 2022
Effect of the LDL receptor mutation type on incident major adverse cardiovascular events in familial hypercholesterolaemiaMartine Paquette, Alain Carrié, Sophie Bernard, et al.
Diabetes, Obesity & Metabolism|March 2, 2019
Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trialAlberto J Lorenzatti, Freddy G Eliaschewitz, Yundai Chen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 30, 2023
Increased FH-Risk-Score and Diabetes Are Cardiovascular Risk Equivalents in Heterozygous Familial HypercholesterolemiaMartine Paquette, Bertrand Cariou, Sophie Bernard, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 23, 2024
Influence of Polygenic Background on the Clinical Presentation of Familial HypercholesterolemiaMark Trinder, Lubomira Cermakova, Isabelle Ruel, et al.
Clinical Cardiology|July 3, 2018
Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trialAlberto J Lorenzatti, Freddy G Eliaschewitz, Yundai Chen, et al.
Tropical Medicine & International Health : TM & IH|August 31, 2023
Validation of the Fatty Liver Index for identifying non-alcoholic fatty liver disease in a Kenyan populationFannie Lajeunesse-Trempe, Michael K Boit, Lydia U Kaduka, et al.
Metabolic Syndrome and Related Disorders|July 28, 2017
Association Between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and the Presence of Metabolic Syndrome in a Predominantly Rural-Based Sub-Saharan African PopulationMartine Paquette, Yascara Grisel Luna Saavedra, Ann Chamberland, et al.
Clinical Biochemistry|January 24, 2020
Circulating PCSK9 is associated with liver biomarkers and hepatic steatosisMartine Paquette, Dany Gauthier, Ann Chamberland, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Journal of Clinical Lipidology|April 1, 2023
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemiaMartine Paquette, Sophie Bernard, Bertrand Cariou, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 26, 2021
Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial HypercholesterolemiaMartine Paquette, Sophie Bernard, Bertrand Cariou, et al.
European Journal of Preventive Cardiology|September 1, 2022
Effect of the LDL receptor mutation type on incident major adverse cardiovascular events in familial hypercholesterolaemiaMartine Paquette, Alain Carrié, Sophie Bernard, et al.
Diabetes, Obesity & Metabolism|March 2, 2019
Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trialAlberto J Lorenzatti, Freddy G Eliaschewitz, Yundai Chen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 30, 2023
Increased FH-Risk-Score and Diabetes Are Cardiovascular Risk Equivalents in Heterozygous Familial HypercholesterolemiaMartine Paquette, Bertrand Cariou, Sophie Bernard, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 23, 2024
Influence of Polygenic Background on the Clinical Presentation of Familial HypercholesterolemiaMark Trinder, Lubomira Cermakova, Isabelle Ruel, et al.
Clinical Cardiology|July 3, 2018
Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trialAlberto J Lorenzatti, Freddy G Eliaschewitz, Yundai Chen, et al.
Tropical Medicine & International Health : TM & IH|August 31, 2023
Validation of the Fatty Liver Index for identifying non-alcoholic fatty liver disease in a Kenyan populationFannie Lajeunesse-Trempe, Michael K Boit, Lydia U Kaduka, et al.
Metabolic Syndrome and Related Disorders|July 28, 2017
Association Between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and the Presence of Metabolic Syndrome in a Predominantly Rural-Based Sub-Saharan African PopulationMartine Paquette, Yascara Grisel Luna Saavedra, Ann Chamberland, et al.
Clinical Biochemistry|January 24, 2020
Circulating PCSK9 is associated with liver biomarkers and hepatic steatosisMartine Paquette, Dany Gauthier, Ann Chamberland, et al.
Pageof 10